LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,243
تعداد مقالات11,323
تعداد مشاهده مقاله81,230,035
تعداد دریافت فایل اصل مقاله116,756,925
niknam, saman, zarredar, habib, Asvadi Kermani, Touraj, Asadi, Milad, Zafari, Venus, Aligholipour Maleki, Raheleh, Shanehbandi, Dariush, hashemzadeh, shahryar. (1405). Evaluation of the LncRNA TMPO AS-1 expression level in breast cancer tissues in comparison with paired normal marginal tissues. سامانه مدیریت نشریات علمی, (), -. doi: 10.30476/mejc.2025.105196.2229
saman niknam; habib zarredar; Touraj Asvadi Kermani; Milad Asadi; Venus Zafari; Raheleh Aligholipour Maleki; Dariush Shanehbandi; shahryar hashemzadeh. "Evaluation of the LncRNA TMPO AS-1 expression level in breast cancer tissues in comparison with paired normal marginal tissues". سامانه مدیریت نشریات علمی, , , 1405, -. doi: 10.30476/mejc.2025.105196.2229
niknam, saman, zarredar, habib, Asvadi Kermani, Touraj, Asadi, Milad, Zafari, Venus, Aligholipour Maleki, Raheleh, Shanehbandi, Dariush, hashemzadeh, shahryar. (1405). 'Evaluation of the LncRNA TMPO AS-1 expression level in breast cancer tissues in comparison with paired normal marginal tissues', سامانه مدیریت نشریات علمی, (), pp. -. doi: 10.30476/mejc.2025.105196.2229
niknam, saman, zarredar, habib, Asvadi Kermani, Touraj, Asadi, Milad, Zafari, Venus, Aligholipour Maleki, Raheleh, Shanehbandi, Dariush, hashemzadeh, shahryar. Evaluation of the LncRNA TMPO AS-1 expression level in breast cancer tissues in comparison with paired normal marginal tissues. سامانه مدیریت نشریات علمی, 1405; (): -. doi: 10.30476/mejc.2025.105196.2229

Evaluation of the LncRNA TMPO AS-1 expression level in breast cancer tissues in comparison with paired normal marginal tissues

Middle East Journal of Cancer
مقالات آماده انتشار، پذیرفته شده، انتشار آنلاین از تاریخ 12 فروردین 1405    اصل مقاله (713.59 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/mejc.2025.105196.2229
نویسندگان
saman niknam1؛ habib zarredar2؛ Touraj Asvadi Kermani1؛ Milad Asadi1؛ Venus Zafari3؛ Raheleh Aligholipour Maleki4؛ Dariush Shanehbandi5؛ shahryar hashemzadeh* 1
1Tabriz University of Medical Science, Tabriz, Iran
2Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran
3Department of basic oncology of health institute of Ege university, Izmir, Turkey
4Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
5Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
چکیده
Background: Breast malignancy is a major public health problem and one of prevalent cancers, which leads to death in women all around the world. Long non-coding RNAs (lncRNAs) are widely studied in the pathogenesis of malignancies. Previous studies have confirmed the correlation of lncRNAs and the cellular development and growth of breast malignancy. The present study aimed to evaluate the expression level of long non-coding RNATMPO antisense RNA 1 (LncRNA TMPO AS-1) in breast cancer tissues and compare it with paired normal marginal tissues.
Methods: Fifty breast cancer patients were included in this case-control study, and tumor tissues and healthy marginal tissues were collected during surgery. Total RNAs were extracted from the normal and cancerous tissues, and after quality control cDNA was synthesized. The TMPO AS-1 expression level was determined by Quantitative polymerase chain reaction (qPCR). The gene expression level and their relationships with the patient’s clinicopathological characteristics were analyzed using appropriate statistical tests.
Results: TMPO Antisense RNA 1(TMPO-AS1) is significantly high expressed in breast cancer tissues compared with normal peripheral tissues (P-value <0.0001, fold change: 1.16). Among the 40 patients exposed to chemotherapy drugs 5-Fluorouracil (5FU) and doxorubicin, the TMPO-AS1 expression level was significantly decreased as compared with the 10 patients unexposed to chemotherapy (P<0.0001, fold change: 0.11). Lymph node metastatic patients (29 positive patients, 21 negative patients) showed high TMPO-AS1 expression level than negative lymph nodes metastasis patients (P = 0.0012, fold change = 1.161).
Conclusion: We demonstrated that TMPO-AS1 is highly expressed and its up-regulation correlates with the pathogenesis and tumorigenesis of breast cancer.

تازه های تحقیق

Habib Zarredar (google scholar)

Milad Asadi (google scholar)

کلیدواژه‌ها
Breast cancer؛ TMPO AS-1؛ Biomarkers؛ Prognoses
مراجع
  1. Azamjah N, Soltan-Zadeh Y, Zayeri F. Global Trend of Breast Cancer Mortality Rate: A 25-Year Study. Asian Pac J Cancer Prev. 2019 20(7):2015-2020. doi: 10.31557/APJCP.2019.20.7.2015.
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
  3. Eliyatkın N, Yalçın E, Zengel B, Aktaş S, Vardar E. Molecular classification of breast carcinoma: from traditional, old-fashioned way to a new age, and a new way. The journal of breast health. 2015 11(2):59. doi: 10.5152/tjbh.2015.1669.
  4. Shakhristova EV, Stepovaya EA, Ryazantseva NV, Nosareva OL, Yakushina VD, Ivanov VV, Novitsky VV. The Role of Protein Oxidative Modification and the Cellular Redox Status in Realization of Apoptosis of MCF-7 Breast Adenocarcmoma Cells. Izvestiia Akademii nauk Seriia biologicheskaia. 2016 (5):453-458.
  5. Viale G. The current state of breast cancer classification. Annals of Oncology. 2012 23:x207-x210. doi: 10.1093/annonc/mds326.
  6. Aftabi Y, Ansarin K, Shanehbandi D, Khalili M, Seyedrezazadeh E, Rahbarnia L, Asadi M, Amiri‐Sadeghan A, Zafari V, Eyvazi S. Long non‐coding RNAs as potential biomarkers in the prognosis and diagnosis of lung cancer: A review and target analysis. IUBMB life. 2021 73(2):307-327. doi: 10.1002/iub.2430. Epub 2020 Dec 24.
  7. Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, Li J, Yao H, Chen K. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. 2023 12(10):11149-11165. doi: 10.1002/cam4.5698.
  8. Zhang L, Wang G, Chen S, Ding J, Ju S, Cao H, Tian H. Depletion of thymopoietin inhibits proliferation and induces cell cycle arrest/apoptosis in glioblastoma cells. World journal of surgical oncology. 2016 14(1):1-8. doi: 10.1186/s12957-016-1018-y.
  9. Brachner A, Foisner R. Lamina-associated polypeptide (LAP) 2α and other LEM proteins in cancer biology. Cancer Biology and the Nuclear Envelope. 2014:143-163. doi: 10.1007/978-1-4899-8032-8_7.
  10. Peric-Hupkes D, van Steensel B. Role of the nuclear lamina in genome organization and gene expression. Cold Spring Harbor symposia on quantitative biology. 2010 75:517-524. doi: 10.1101/sqb.2010.75.014. Epub 2011 Jan 5.
  11. Capo-chichi CD, Cai KQ, Smedberg J, Ganjei-Azar P, Godwin AK, Xu XX. Loss of A-type lamin expression compromises nuclear envelope integrity in breast cancer. Chinese journal of cancer. 2011 30(6):415-425. doi: 10.5732/cjc.010.10566.
  12. Liu G, Yang H, Cao L, Han K, Li G. LncRNA TMPO-AS1 Promotes Proliferation and Invasion by Sponging miR-383-5p in Glioma Cells. Cancer Management and Research. 2020 12:12001. doi: 10.2147/CMAR.S282539. eCollection 2020.
  13. Mitobe Y, Ikeda K, Sato W, Kodama Y, Naito M, Gotoh N, Miyata K, Kataoka K, Sasaki H, Horie‐Inoue K. Proliferation‐associated long noncoding RNA, TMPO‐AS1, is a potential therapeutic target for triple‐negative breast cancer. Cancer science. 2020 111(7):2440. doi: 10.1111/cas.14498. Epub 2020 Jun 13.
  14. Huang W, Su X, Yan W, Kong Z, Wang D, Huang Y, Zhai Q, Zhang X, Wu H, Li Y. Overexpression of AR‐regulated lncRNA TMPO‐AS1 correlates with tumor progression and poor prognosis in prostate cancer. The Prostate. 2018 78(16):1248-1261. doi: 10.1002/pros.23700. Epub 2018 Aug 13.
  15. Mitobe Y, Ikeda K, Suzuki T, Takagi K, Kawabata H, Horie-Inoue K, Inoue S. ESR1-stabilizing long noncoding RNA TMPO-AS1 promotes hormone-refractory breast cancer progression. Molecular and cellular biology. 2019 39(23). doi: 10.1128/MCB.00261-19.
  16. Osielska MA, Jagodziński PP. Long non-coding RNA as potential biomarkers in non-small-cell lung cancer: What do we know so far? Biomedicine & Pharmacotherapy. 2018 101:322-333. doi: 10.1016/j.biopha.2018.02.099.
  17. Li D, Ainiwaer J, Sheyhiding I, Zhang Z, Zhang L. Identification of key long non-coding RNAs as competing endogenous RNAs for miRNA-mRNA in lung adenocarcinoma. Eur Rev Med Pharmacol Sci. 2016 20(11):2285-2295.
  18. Peng F, Wang R, Zhang Y, Zhao Z, Zhou W, Chang Z, Liang H, Zhao W, Qi L, Guo Z. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Molecular cancer. 2017 16(1):1-12. doi: 10.1186/s12943-017-0666-z.
  19. Gang X, Yuan M, Zhang J. Long non-coding RNA TMPO-AS1 promotes cervical cancer cell proliferation, migration, and invasion by regulating miR-143-3p/ZEB1 axis. Cancer management and research. 2020 12:1587-1599. doi: 10.2147/CMAR.S226409.
  20. Guo X, Wang Y. LncRNA TMPO‐AS1 promotes hepatocellular carcinoma cell proliferation, migration and invasion through sponging miR‐329‐3p to stimulate FOXK1‐mediated AKT/mTOR signaling pathway. Cancer Medicine. 2020 9(14):5235-5246. doi: 10.1002/cam4.3046. 
  21. Cui H, Zhao J. LncRNA TMPO‐AS1 serves as a ceRNA to promote osteosarcoma tumorigenesis by regulating miR‐199a‐5p/WNT7B axis. Journal of cellular biochemistry. 2020 121(3):2284-2293. doi: 10.1002/jcb.29451.
  22. Ning X, Zhao J, He F, Yuan Y, Li B, Ruan J. Long non‑coding RNA TMPO‑AS1 facilitates chemoresistance and invasion in breast cancer by modulating the miR‑1179/TRIM37 axis. Oncology Letters. 2021 22(1):1-9. doi: 10.3892/ol.2021.12761.
  23. Zhu D, Lv W, Zhou X, He Y, Yao H, Yu Y, Zhang G, Zhang Q. Long non‑coding RNA TMPO‑AS1 promotes tumor progression via sponging miR‑140‑5p in breast cancer. Experimental and Therapeutic Medicine. 2021 21(1):1-1. doi: 10.3892/etm.2020.9449.
  24. Yu X, Lin Q, Liu F, Yang F, Mao J, Chen X. LncRNA TMPO-AS1 facilitates the proliferation and metastasis of NSCLC cells by up-regulating ERBB2 via sponging miR-204-3p. International Journal of Immunopathology and Pharmacology. 2020 34:2058738420958947. doi: 10.1177/2058738420958947
  25. Zarredar H, Ansarin K, Baradaran B, Ahdi Khosroshahi S, Farajnia S. Potential molecular targets in the treatment of lung cancer using siRNA technology. Cancer investigation. 2018 36(1):37-58. doi: 10.1080/07357907.2017.
  26. Luo H, Yang L, Liu C, Wang X, Dong Q, Liu L, Wei Q. TMPO-AS1/miR-98-5p/EBF1 feedback loop contributes to the progression of bladder cancer. The international journal of biochemistry & cell biology. 2020 122:105702. doi: 10.1016/j.biocel.2020.105702. 
  27. Xing B, Qiao X-F, Qiu Y-H, Li X. TMPO-AS1 Regulates the Aggressiveness-Associated Traits of Nasopharyngeal Carcinoma Cells Through Sponging miR-320a. Cancer Management and Research. 2021 13:415. doi: 10.2147/CMAR.S285113.
  28. Peng X, Yan J, Cheng F. LncRNA TMPO-AS1 up-regulates the expression of HIF-1α and promotes the malignant phenotypes of retinoblastoma cells via sponging miR-199a-5p. Pathology-Research and Practice. 2020 216(4):152853. doi: 10.1016/j.prp.2020.152853.
  29. Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. Cancers (Basel). 2021 13(17). doi: 10.3390/cancers13174455.
  30. Malkas LH, Herbert BS, Abdel-Aziz W, Dobrolecki LE, Liu Y, Agarwal B, Hoelz D, Badve S, Schnaper L, Arnold RJ et al. A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proceedings of the National Academy of Sciences of the United States of America. 2006 103(51):19472-19477. doi: 10.1073/pnas.0604614103.
  31. Ahn SK, Jung SY. Current Biomarkers for Precision Medicine in Breast Cancer. Advances in experimental medicine and biology. 2021 1187:363-379. doi: 10.1007/978-981-32-9620-6_18.
آمار
تعداد مشاهده مقاله: 4
تعداد دریافت فایل اصل مقاله: 1


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب